The Diagnostic Impact of Color Vision - Summary - MDSpire

The Diagnostic Impact of Color Vision

Study suggests reduced survival in bladder cancer patients with color vision deficiency

  • March 30, 2026

  • 2 min

Share

Objective:

To investigate the influence of color vision deficiency (CVD) on the detection and survival outcomes of bladder and colorectal cancers, highlighting its potential implications for patient care.

Approach:
    Key Findings:
    • Patients with bladder cancer and CVD showed lower overall survival compared to controls (p-value needed).
    • A 20-year analysis indicated higher mortality in bladder cancer patients with CVD (p-value needed).
    • No significant survival difference was found in colorectal cancer patients with and without CVD.
    Interpretation:

    Impaired recognition of visible blood in urine may lead to delayed presentation and poorer outcomes in bladder cancer for individuals with CVD, as they may misinterpret or overlook these critical symptoms.

    Limitations:
    • Reliance on diagnostic coding within electronic health records may introduce biases.
    • Limited availability of staging data restricts assessment of disease severity at presentation.
    Conclusion:

    The study highlights a potential diagnostic gap related to visual impairment affecting detection pathways in bladder cancer, emphasizing the need for awareness and assessment of CVD in clinical practice, with less impact observed in colorectal cancer.

Original Source(s)

The Diagnostic Impact of Color Vision

  • March 30, 2026

Related Content

Proton Therapy in Early-Onset Locally Advanced Rectal Cancer: The Importance of Fertility-Preserving Multimodality Care

The rising incidence and mortality of early-onset colorectal cancer (EOCRC), defined as disease occurring in patients younger than 50, has emerged as a clinically significant trend with implications for screening, diagnosis, and survivorship.

  • April 28, 2026

  • 5 min
This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min
The Next Wave of Immune Cell Therapy

From CAR T to eTCR: New immune cell therapies push beyond blood cancers

  • April 1, 2026

  • 18 min